BioPharm America™ Features Top Industry Decision-Makers in Life Science Partnering
BioPharm America™ Features Top Industry Decision-Makers in Life Science Partnering
Carlsbad, CA. and Atlanta, GA., June 25, 2008: Navigating a shifting landscape of bio-pharma deal making will be the
focus for discussions among licensing and business development executives
from Bayer Schering, Novo Nordisk, Novartis, Pfizer, Johnson & Johnson
and Shire Pharmaceuticals at BioPharm
America™ in Atlanta, September 9-10, 2008.
The backdrop for intensive partnering meetings during BioPharm America
is a rich program of keynote speeches, panel discussions and workshops
featuring decision makers from across the biotechnology value-chain.
The speaker line-up includes the following pharma executives:
- Dr. Nils Debus, Senior Director, Global Business Development and Licensing at Bayer Schering.
- Dr. Aya Jakobovits, Chief Scientific Officer, Agensys - Astellas Group
- Dr. Tomas Landh, Director, Strategy and Sourcing at Novo Nordisk.
- Dr. Manuel Litchman, Vice President & Head, Oncology Business Development and Licensing with Novartis Pharmaceuticals Corporation.
- Gwen A. Melincoff, Senior Vice President, Business Development for Shire Pharmaceuticals
- Sun Park, Vice President, Corporate Development at Medlmmune
- Dr. Ellen Strahlman, Vice President, Licensing, Worldwide Business Development for Pfizer
- Dr. Rob Wills, Vice President, Alliance Management, Pharmaceuticals Group at Johnson & Johnson
- Dr. Steven Xanthoudakis, Director, Licensing and External Research with Merck Frosst Canada
Topics for workshop and panel sessions reflect diverse issues for partnering
and financing in the life science industry today, providing an up-to-date
industry perspective on licensing, mergers and acquisitions, and alliances.
Plenary topics include:
- How is the Evolving Bio-Pharma Drug Development Landscape Affecting Transactions?
- Recent Deal-making – What is Hot and What is Not?
Debate and discussion in panel sessions will take on provocative issues such as:
- How Mid-size Pharma Competes in an Environment Dominated by Big Pharma
- Biologics – The Solution to Big Pharma's Problems?
- Exploring the Link Between Portfolio Strategy and Business Development
- New Financing Trends in Drug Development; the Role of Big Pharma and Private Equity
Special workshops include:
- Translational Medicine – How do we Fund Novel, Breakthrough Research more Efficiently?
- ABCs of In-Licensing
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
BD Group's conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe's largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- EuroMedtech™, EBD Group's partnering event for the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- Partnering for Global Impact®, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences at industry events.
Outside of the conference format, EBD Group's consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com or contact:
Constantine Theodoropulos
EBD Group
+1 617 816 4637
ctheodoropulos@ebdgroup.com
About MassBio
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
For more information please visit www.massbio.org.
